Q2 2026 Acurx Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Acurx Pharmaceuticals Inc (ACXP) received FDA guidance indicating openness to a single Phase 3 trial (IBZ-ASPIRE) for NDA filing, contingent on robust efficacy data and totality of evidence.
- The company secured FDA conditional acceptance and USPTO Trademark Allowance for the proprietary name 'Syfbezi' for ibezapolstat, advancing its commercial identity.
- Acurx Pharmaceuticals Inc (ACXP) expanded its scientific partnership with Leiden University Medical Center to further develop DNA pol III C inhibitors, including research on MRSA.
- Preclinical data presented at ESCMID demonstrated that ibezapolstat and other DNA pol III C inhibitors preserve gut microbiome diversity while effectively targeting Gram-positive pathogens, a key differentiator.
- The company has sufficient API and formulated product ready to support both the PATHFINDER and ASPIRE trials, with cash totaling $10.7 million, funding operations for at least one year.
- The PATHFINDER trial is fully funded and, if successful, could provide a second pathway to FDA approval under the LPAD pathway for recurrent C. diff, potentially reducing the cost and scope of a pivotal trial.
- Acurx Pharmaceuticals Inc (ACXP) reported a net loss of $2.3 million for Q2 2026, with increased R&D expenses due to manufacturing and consulting costs for the new recurrent CDI trial program.
- The Phase 3 ASPIRE trial is not yet funded, and the company is still seeking funding from public or private sources or partnerships, creating uncertainty about the timeline.
- The FDA's acceptance of a single Phase 3 trial is conditional and not guaranteed, as it depends on the robustness of clinical efficacy results and the totality of evidence at a pre-NDA meeting.
- The company's cash position, while improved, remains limited at $10.7 million, and the need for additional funding for the ASPIRE trial could lead to further dilution or delays.
- The international Phase 3 trial has not yet begun site screening, and the company has not provided specific details on the countries involved, indicating early-stage planning.
- The PATHFINDER trial enrollment is not expected to start until Q4 2026, and the ASPIRE trial timeline remains uncertain, potentially delaying potential commercialization.
Greetings. Welcome to Acurx Pharmaceuticals to discuss second quarter 2026 Financial Results on August 14, 2026, Conference Call and provide business update. (Operator Instructions) Please note, this conference is being recorded. I'll now turn the conference over to Rob Shawah, Chief Financial Officer. Thank you. You may begin.
Thank you, Rob. Good morning, and welcome to our call. This morning, we issued a press release providing financial results and company highlights for the second quarter of 2026, which is available on our website at acurxpharma.com.
Joining me today is Dave Luci, President and CEO of Acurx, who will start by providing a corporate update and outlook. Following that, I'll provide some highlights of the financials from the second quarter ended June 30 and then turn the call back over to Dave for his closing remarks.
As a reminder, during today's call, we'll be making certain forward-looking statements, which are based on current information,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
